Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.9% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price rose 8.9% on Wednesday . The stock traded as high as $3.27 and last traded at $3.2350. Approximately 9,694,861 shares were traded during trading, a decline of 41% from the average daily volume of 16,502,961 shares. The stock had previously closed at $2.97.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. JPMorgan Chase & Co. reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Morgan Stanley upped their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Stock Performance

The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.92 billion, a PE ratio of -3.01 and a beta of 1.05. The stock’s 50 day simple moving average is $3.26 and its two-hundred day simple moving average is $3.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.50) earnings per share. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $3.52, for a total transaction of $105,600.00. Following the transaction, the director owned 6,199,863 shares in the company, valued at approximately $21,823,517.76. The trade was a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock in a transaction on Monday, March 9th. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30. Following the transaction, the chief executive officer owned 2,262,085 shares in the company, valued at $7,577,984.75. The trade was a 1.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 96,254 shares of company stock valued at $320,369 over the last ninety days. Corporate insiders own 8.43% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in RXRX. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares during the period. State Street Corp boosted its stake in shares of Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after purchasing an additional 7,064,963 shares during the period. Norges Bank purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at $23,473,000. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 11.2% in the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $7,370,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.